[go: up one dir, main page]

EE05662B1 - Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine - Google Patents

Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Info

Publication number
EE05662B1
EE05662B1 EEP200100549A EEP200100549A EE05662B1 EE 05662 B1 EE05662 B1 EE 05662B1 EE P200100549 A EEP200100549 A EE P200100549A EE P200100549 A EEP200100549 A EE P200100549A EE 05662 B1 EE05662 B1 EE 05662B1
Authority
EE
Estonia
Prior art keywords
composition
hiku
antagonist
sub
treating fibrosis
Prior art date
Application number
EEP200100549A
Other languages
English (en)
Estonian (et)
Inventor
Gotwals Philip
R. Lobb Roy
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200100549A publication Critical patent/EE200100549A/xx
Publication of EE05662B1 publication Critical patent/EE05662B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100549A 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine EE05662B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (2)

Publication Number Publication Date
EE200100549A EE200100549A (et) 2002-12-16
EE05662B1 true EE05662B1 (et) 2013-06-17

Family

ID=26828876

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100549A EE05662B1 (et) 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Country Status (31)

Country Link
US (3) US6652856B2 (pt)
EP (1) EP1173201B1 (pt)
JP (3) JP5483515B2 (pt)
KR (3) KR100746522B1 (pt)
CN (3) CN100360183C (pt)
AT (1) ATE298249T1 (pt)
AU (1) AU783054B2 (pt)
BG (2) BG65578B1 (pt)
BR (1) BR0010669A (pt)
CA (1) CA2370814C (pt)
CY (1) CY1106046T1 (pt)
CZ (1) CZ301636B6 (pt)
DE (1) DE60020955T2 (pt)
DK (1) DK1173201T3 (pt)
EA (1) EA006681B1 (pt)
EE (1) EE05662B1 (pt)
ES (1) ES2243259T3 (pt)
GE (1) GEP20063844B (pt)
HK (1) HK1041452B (pt)
HU (1) HU226383B1 (pt)
IL (5) IL145898A0 (pt)
IS (1) IS2259B (pt)
MX (1) MXPA01010612A (pt)
NO (1) NO330221B1 (pt)
NZ (2) NZ541431A (pt)
PL (1) PL198975B1 (pt)
PT (1) PT1173201E (pt)
RS (2) RS20080471A (pt)
SK (1) SK287328B6 (pt)
TR (1) TR200200027T2 (pt)
WO (1) WO2000064474A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100746522B1 (ko) * 1999-04-22 2007-08-07 바이오겐 아이덱 엠에이 인코포레이티드 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
CA2375827C (en) * 1999-06-01 2017-01-10 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
WO2001070210A2 (en) * 2000-03-17 2001-09-27 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
EP1341497A4 (en) * 2000-11-02 2005-10-19 Smithkline Beecham Corp RECEPTOR-LIPID ANTAGONIST CONJUGATES AND DELIVERY VEHICLES CONTAINING THE SAME
HUP0402250A3 (en) * 2001-04-13 2007-06-28 Biogen Idec Inc Antibodies to vla-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US9382322B2 (en) * 2003-10-17 2016-07-05 Rehab Al-Jamal Tissue repair by modulation of beta-1 integrin biological function
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP5496658B2 (ja) * 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
EP2543389A3 (en) * 2007-08-02 2013-04-24 Gilead Biologics, Inc. Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
EP2832368B1 (en) * 2012-03-28 2021-11-10 Hiroshima University Fibrosis suppression by inhibiting integrin alpha8beta1 function
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
WO2019163927A1 (en) * 2018-02-23 2019-08-29 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
KR20250093432A (ko) 2019-08-28 2025-06-24 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
ATE150319T1 (de) * 1992-01-13 1997-04-15 Biogen Inc Behandlung von asthma
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
EP0682529B2 (en) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
AU703152B2 (en) * 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
PT759302E (pt) * 1994-04-26 2001-01-31 Akzo Nobel Nv Farmaco para o tratamento da artrite reumatoide
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
IL134288A0 (en) * 1997-08-08 2001-04-30 Univ California TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
KR100746522B1 (ko) * 1999-04-22 2007-08-07 바이오겐 아이덱 엠에이 인코포레이티드 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
IL182908A (en) 2010-11-30
SK15202001A3 (sk) 2002-09-10
BG65578B1 (bg) 2009-01-30
US20040037827A1 (en) 2004-02-26
AU783054B2 (en) 2005-09-22
BG106118A (en) 2002-05-31
CN1191860C (zh) 2005-03-09
CN100360183C (zh) 2008-01-09
US20050281818A1 (en) 2005-12-22
CN1679935A (zh) 2005-10-12
PL351916A1 (en) 2003-06-30
AU4480000A (en) 2000-11-10
IL182908A0 (en) 2007-08-19
JP5483515B2 (ja) 2014-05-07
IL206830A0 (en) 2010-12-30
IL206830A (en) 2013-06-27
NO20015122D0 (no) 2001-10-19
PL198975B1 (pl) 2008-08-29
IL145898A (en) 2007-07-24
IS2259B (is) 2007-06-15
CN1356911A (zh) 2002-07-03
WO2000064474A8 (en) 2001-04-05
DE60020955T2 (de) 2006-05-11
PT1173201E (pt) 2005-08-31
CA2370814C (en) 2010-07-06
ATE298249T1 (de) 2005-07-15
KR20070050979A (ko) 2007-05-16
EE200100549A (et) 2002-12-16
CY1106046T1 (el) 2011-04-06
TR200200027T2 (tr) 2002-07-22
NO330221B1 (no) 2011-03-07
ES2243259T3 (es) 2005-12-01
GEP20063844B (en) 2006-06-12
YU74901A (sh) 2004-07-15
CA2370814A1 (en) 2000-11-02
CZ20013754A3 (cs) 2002-07-17
HK1076379A1 (zh) 2006-01-20
NO20015122L (no) 2001-12-21
EA006681B1 (ru) 2006-02-24
IS6105A (is) 2001-10-11
JP2014065747A (ja) 2014-04-17
KR20070102760A (ko) 2007-10-19
CN1332714C (zh) 2007-08-22
DE60020955D1 (de) 2005-07-28
HUP0201015A3 (en) 2004-12-28
IL206829A (en) 2013-06-27
KR100837715B1 (ko) 2008-06-13
US20020182213A1 (en) 2002-12-05
CZ301636B6 (cs) 2010-05-12
HUP0201015A2 (hu) 2002-07-29
JP2007182453A (ja) 2007-07-19
HK1041452B (en) 2005-10-14
CN1596979A (zh) 2005-03-23
BG110115A (en) 2008-12-30
RS20080471A (sr) 2010-12-31
NZ515053A (en) 2004-02-27
SK287328B6 (sk) 2010-07-07
EA200101116A1 (ru) 2002-04-25
US6652856B2 (en) 2003-11-25
EP1173201A1 (en) 2002-01-23
HK1041452A1 (en) 2002-07-12
MXPA01010612A (es) 2003-09-04
KR20020000221A (ko) 2002-01-05
JP2002542300A (ja) 2002-12-10
NZ541431A (en) 2008-01-31
KR100746522B1 (ko) 2007-08-07
BG66149B1 (bg) 2011-08-31
BR0010669A (pt) 2002-02-19
RS50086B (sr) 2009-01-22
IL145898A0 (en) 2002-07-25
HU226383B1 (hu) 2008-10-28
WO2000064474A1 (en) 2000-11-02
IL206829A0 (en) 2010-12-30
DK1173201T3 (da) 2005-09-12
EP1173201B1 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
EE05662B1 (et) Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
ATE327004T1 (de) Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
LU93274I2 (fr) Elotuzumab
BR9812886A (pt) Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
NO984564D0 (no) FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister
EA200100041A1 (ru) Способ лечения
MEP20308A (en) THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
EP1666063A3 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ES1031656Y (es) Seccion mixta de madera y hormigon, aplicable en construccion.

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20150421